Press

release
SinSa Labs
2015-01-08

New class of antibiotics

bioengineered to deter the development of antibiotic
resistance
SinSa Labs today announced the signing of a License agreement with Singapore Health
Services and ETPL, A*STARs technology transfer arm, regarding a technology developed
at the Singapore Eye Research Institute (SERI) and Bioinformatics Institute (BII), A*STAR
that deters the development of antibiotic resistance. This agreement provides SinSa Labs
with a technology platform leading to a new class of antibiotics that kill bacteria quickly at
a low dose and deters antibiotic resistance.

Currently the company is developing its first antibiotic (Dorzidin) suitable for treating
antibiotic-resistant eye and ear infections. SinSa Labs is seeking series A financing, as will
be outlined in an offer to invest.

Professor Roger Beuerman, SinSas co-founder and leader of the research team behind
the new class of antibiotics, said, It is exciting and promising that this scientific research
will be commercialized by SinSa Labs and made available to patients. Many lives can be
saved.

According to the U.S. Food and Drug Administration (FDA), almost all important bacterial
infections in the United States and throughout the world are becoming resistant to
antibiotics. (www.fda.gov). With Sinsa Labs SpearHead Technology (SHT) it is possible to
counteract this bleak future.

SinSa Labs is developing the SpearHead Technology, using bioengineered molecules to

penetrate and breakdown the membrane of the bacteria. With this technique both Gram-
negative and Gram-positive bacteria are rapidly killed. SHT antibiotics are powerful
antibiotics on their own. In addition, some SHT antibiotics at very low concentrations work
synergistically with traditional antibiotics, thereby increasing the therapeutic window and
decreasing the amount of antibiotic substance used.
For further information please visit www.sinsalabs.com


Contact:
Roger Beuerman Ph.D., CSO SinSa Labs
Magnus Precht, CEO Sinsa Labs
rbeuerman@sinsalabs.com
mprecht@sinsalabs.com
Urban Olson, General Counsel SinSa Labs,
Phone: +1- 609 356 2863 or
uolson@sinsalabs.com
+46-708 20 50 41